BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25496985)

  • 21. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and neurophysiological variability in Andersen-Tawil syndrome.
    Kokubun N; Aoki R; Nagashima T; Komagamine T; Kuroda Y; Horie M; Hirata K
    Muscle Nerve; 2019 Dec; 60(6):752-757. PubMed ID: 31509255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular genetic diagnostics of the cause of ventricular arrhythmias in children].
    Brøndberg AK; Bjerre JV; Nielsen JC; Jensen HK
    Ugeskr Laeger; 2015 Sep; 177(38):V04150366. PubMed ID: 26376421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Andersen-Tawil syndrome. Efficacy of class IC drugs].
    Makarov LM; Komoliatova VN; Kolosov VO; Fedina NN; Solokhin IuA
    Kardiologiia; 2013; 53(1):91-6. PubMed ID: 23548357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1.
    Mazzanti A; Guz D; Trancuccio A; Pagan E; Kukavica D; Chargeishvili T; Olivetti N; Biernacka EK; Sacilotto L; Sarquella-Brugada G; Campuzano O; Nof E; Anastasakis A; Sansone VA; Jimenez-Jaimez J; Cruz F; Sánchez-Quiñones J; Hernandez-Afonso J; Fuentes ME; Średniawa B; Garoufi A; Andršová I; Izquierdo M; Marinov R; Danon A; Expósito-García V; Garcia-Fernandez A; Muñoz-Esparza C; Ortíz M; Zienciuk-Krajka A; Tavazzani E; Monteforte N; Bloise R; Marino M; Memmi M; Napolitano C; Zorio E; Monserrat L; Bagnardi V; Priori SG
    J Am Coll Cardiol; 2020 Apr; 75(15):1772-1784. PubMed ID: 32299589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotype variability in patients carrying KCNJ2 mutations.
    Kimura H; Zhou J; Kawamura M; Itoh H; Mizusawa Y; Ding WG; Wu J; Ohno S; Makiyama T; Miyamoto A; Naiki N; Wang Q; Xie Y; Suzuki T; Tateno S; Nakamura Y; Zang WJ; Ito M; Matsuura H; Horie M
    Circ Cardiovasc Genet; 2012 Jun; 5(3):344-53. PubMed ID: 22589293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure of radiofrequency catheter ablation and success of flecainide to suppress premature ventricular contractions in Andersen-Tawil syndrome: A case report.
    Yilmaz S; Kanat S
    J Electrocardiol; 2021; 68():37-40. PubMed ID: 34311212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined inhibition of Na⁺ and Ca²⁺ channels: a novel paradigm for the treatment of incessant ventricular arrhythmias in Andersen-Tawil syndrome.
    Janson CM; Poelzing S; Shah MJ
    Heart Rhythm; 2014 Feb; 11(2):318-20. PubMed ID: 24211314
    [No Abstract]   [Full Text] [Related]  

  • 30. Andersen-Tawil syndrome with early fixed myopathy.
    Lefter S; Hardiman O; Costigan D; Lynch B; McConville J; Hand CK; Ryan AM
    J Clin Neuromuscul Dis; 2014 Dec; 16(2):79-82. PubMed ID: 25415519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrophysiological mechanisms of ventricular arrhythmias in relation to Andersen-Tawil syndrome under conditions of reduced IK1: a simulation study.
    Sung RJ; Wu SN; Wu JS; Chang HD; Luo CH
    Am J Physiol Heart Circ Physiol; 2006 Dec; 291(6):H2597-605. PubMed ID: 16877549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.
    Zhang L; Benson DW; Tristani-Firouzi M; Ptacek LJ; Tawil R; Schwartz PJ; George AL; Horie M; Andelfinger G; Snow GL; Fu YH; Ackerman MJ; Vincent GM
    Circulation; 2005 May; 111(21):2720-6. PubMed ID: 15911703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of flecainide on T-wave alternans in Andersen-Tawil syndrome.
    Hayashi H; Kawaguchi T; Horie M
    Ann Noninvasive Electrocardiol; 2014 Jul; 19(4):383-6. PubMed ID: 25040481
    [No Abstract]   [Full Text] [Related]  

  • 35. [QTU pattern in a patient with the Anderson-Tawil syndrome].
    Ciurzyński M; Bienias P; Kostera-Pruszczyk A; Pruszczyk P
    Kardiol Pol; 2010 Mar; 68(3):339-41; discussion 342. PubMed ID: 20411461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KCNJ2 variant of unknown significance reclassified as long QT syndrome causing ventricular fibrillation.
    Obeyesekere MN; Klein GJ; Conacher S; Krahn AD
    Can J Cardiol; 2011; 27(6):870.e11-3. PubMed ID: 21875779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mosaic KCNJ2 mutation in Andersen-Tawil syndrome: targeted deep sequencing is useful for the detection of mosaicism.
    Hasegawa K; Ohno S; Kimura H; Itoh H; Makiyama T; Yoshida Y; Horie M
    Clin Genet; 2015 Mar; 87(3):279-83. PubMed ID: 24635491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible Dilated Cardiomyopathy Caused by a High Burden of Ventricular Arrhythmias in Andersen-Tawil Syndrome.
    Rezazadeh S; Guo J; Duff HJ; Ferrier RA; Gerull B
    Can J Cardiol; 2016 Dec; 32(12):1576.e15-1576.e18. PubMed ID: 27789106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype.
    Limberg MM; Zumhagen S; Netter MF; Coffey AJ; Grace A; Rogers J; Böckelmann D; Rinné S; Stallmeyer B; Decher N; Schulze-Bahr E
    Basic Res Cardiol; 2013 May; 108(3):353. PubMed ID: 23644778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral verapamil effectively suppressed complex ventricular arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome.
    Erdogan O; Aksoy A; Turgut N; Durusoy E; Samsa M; Altun A
    J Electrocardiol; 2008; 41(4):325-8. PubMed ID: 18353348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.